PDZK1 regulates breast cancer resistance protein in small intestine

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 2148-2154

  Shimizu, Takuya ^a   Sugiura, Tomoko ^a   Wakayama, Tomohiko ^a   Kijima, Ai ^a   Nakamichi, Noritaka ^a   Iseki, Shoichi ^a   Silver, David L ^b   Kato, Yukio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CIMETIDINE; GLYCOPROTEIN P; POSTSYNAPTIC DENSITY PROTEIN 95;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESISTANCE; DRUG TRANSPORT; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTESTINE ABSORPTION; INTESTINE BRUSH BORDER MEMBRANE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SMALL INTESTINE; TRANSCYTOSIS; WESTERN BLOTTING; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE; CIMETIDINE; INTESTINAL ABSORPTION; INTESTINE, SMALL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; P-GLYCOPROTEINS; PROTEIN INTERACTION DOMAINS AND MOTIFS;

MUS;

EID: 80054735135     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040295     Document Type: Article

References (41)

1. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ, Enomoto A, Sakamoto S, Hirata T, Tomita K, et al. (2004) The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem 279:45942-45950. (Pubitemid 39491587)
2. Avdeef A and Berger CM (2001) pH-metric solubility. 3. Dissolution titration template method for solubility determination. Eur J Pharm Sci 14:281-291. (Pubitemid 33001620)
3. Chu XY, Sánchez-Castaño GP, Higaki K, Oh DM, Hsu CP, and Amidon GL (2001) Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther 299:575-582.
4. Dahan A and Amidon GL (2009) Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 6:19-28.
5. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20. (Pubitemid 34124034)
6. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447-452. (Pubitemid 34563537)
7. Ghosh MG, Thompson DA, and Weigel RJ (2000) PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 60:6367-6375.
8. Gisler SM, Pribanic S, Bacic D, Forrer P, Gantenbein A, Sabourin LA, Tsuji A, Zhao ZS, Manser E, Biber J, et al. (2003) PDZK1: I. A major scaffolder in brush borders of proximal tubular cells. Kidney Int 64:1733-1745. (Pubitemid 37323702)
9. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
10. Hillesheim J, Riederer B, Tuo B, Chen M, Manns M, Biber J, Yun C, Kocher O, and Seidler U (2007) Down regulation of small intestinal ion transport in PDZK1- (CAP70/NHERF3) deficient mice. Pflugers Arch 454:575-586. (Pubitemid 46872904)
11. Hillier BJ, Christopherson KS, Prehoda KE, Bredt DS, and Lim WA (1999) Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science 284:812-815. (Pubitemid 29291348)
12. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, and Hosoya T (2004) Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15:164-173. (Pubitemid 38020708)
13. Ikebuchi Y, Ito K, Takada T, Anzai N, Kanai Y, and Suzuki H (2010) Receptor for activated C-kinase 1 regulates the cell surface expression and function of ATP binding cassette G2. Drug Metab Dispos 38:2320-2328.
14. Kato Y, Yoshida K, Watanabe C, Sai Y, and Tsuji A (2004) Screening of the interaction between xenobiotic transporters and PDZ proteins. Pharm Res 21:1886-1894. (Pubitemid 39390102)
15. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, and Niemi M (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203.
16. Kocher O, Comella N, Gilchrist A, Pal R, Tognazzi K, Brown LF, and Knoll JH (1999) PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab Invest 79:1161-1170. (Pubitemid 29444548)
17. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, et al. (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5:e1000504.
18. Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, and Schellens JH (2007) A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13:3276-3285. (Pubitemid 46944913)
19. Lan D and Silver DL (2005) Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. J Biol Chem 280:23390-23396. (Pubitemid 40853253)
20. Lentz KA, Polli JW, Wring SA, Humphreys JE, and Polli JE (2000) Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 17:1456-1460. (Pubitemid 32217554)
21. Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, Zaccolo M, Jalink K, Li M, Nelson DJ, Schuetz JD, et al. (2007) Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131:940-951. (Pubitemid 350138082)
22. Lilja JJ, Raaska K, and Neuvonen PJ (2005) Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 61:337-340. (Pubitemid 41569306)
23. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y, Chiba T, Tadokoro S, et al. (2009) Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 1:5ra11.
24. Nagai S, Takenaka K, Nachagari D, Rose C, Domoney K, Sun D, Sparreboom A, and Schuetz JD (2011) Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 71:1781-1791.
25. Oberle RL and Amidon GL (1987) The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 15:529-544.
26. Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, Ohnishi S, and Isomura Y (2006) What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab Pharmacokinet 21:238-244.
27. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152. (Pubitemid 40096463)
28. Piyapolrungroj N, Li C, Pisoni RL, and Fleisher D (1999) Cimetidine transport in brush-border membrane vesicles from rat small intestine. J Pharmacol Exp Ther 289:346-353. (Pubitemid 29156048)
29. Piyapolrungroj N, Zhou YS, Li C, Liu G, Zimmermann E, and Fleisher D (2000) Cimetidine absorption and elimination in rat small intestine. Drug Metab Dispos 28:65-72. (Pubitemid 30027514)
30. Reymond JP, Steimer JL, and Niederberger W (1988) On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 16:331-353.
31. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, and Kirch W (2007) Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669-678. (Pubitemid 46625125)
32. Shugarts S and Benet LZ (2009) The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039-2054.
33. Sugiura T, Kato Y, Wakayama T, Silver DL, Kubo Y, Iseki S, and Tsuji A (2008) PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice. Drug Metab Dispos 36:1181-1188. (Pubitemid 351717477)
34. Sugiura T, Otake T, Shimizu T, Wakayama T, Silver DL, Utsumi R, Nishimura T, Iseki S, Nakamichi N, Kubo Y, et al. (2010) PDZK1 regulates organic anion transporting polypeptide Oatp1a in mouse small intestine. Drug Metab Pharmacokinet 25:588-598.
35. Sugiyama T, Shuto T, Suzuki S, Sato T, Koga T, Suico MA, Kusuhara H, Sugiyama Y, Cyr DM, and Kai H (2011) Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1. Biochem Biophys Res Commun 404:853-858.
36. van der Harst P, Bakker SJ, de Boer RA, Wolffenbuttel BH, Johnson T, Caulfield MJ, and Navis G (2010) Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet 19:387-395.
37. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, and Langdon SP (2007) Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 106:461-468. (Pubitemid 47302473)
38. Wang H, Lee EW, Cai X, Ni Z, Zhou L, and Mao Q (2008) Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry 47:13778-13787.
39. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, et al. (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84:95-103. (Pubitemid 351861490)
40. Zachos NC, Li X, Kovbasnjuk O, Hogema B, Sarker R, Lee LJ, Li M, de Jonge H, and Donowitz M (2009) NHERF3 (PDZK1) contributes to basal and calcium inhibition of NHE3 activity in Caco-2BBe cells. J Biol Chem 284:23708-23718.
41. Zhou SY, Piyapolrungroj N, Pao L, Li C, Liu G, Zimmermann E, and Fleisher D (1999) Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine. Pharm Res 16:1781-1785. (Pubitemid 29530414)